Claims
- 1. A prostaglandin D represented by formula (I):
- where (X) is ##STR23## R.sub.1 is a physiologically acceptable alkyl ester residue; R.sub.2 is hydrogen or methyl;
- R.sub.3 is hydroxyl, methyl or hydroxymethyl;
- and wherein carbons at the 2-3 positions may have a double bond.
- 2. A prostaglandin D represented by formula (I): ##STR24## where (X) is) ##STR25## R.sub.1 is hydrogen, a physiologically accepted salt residue or a physiologically acceptably ester residue;
- R.sub.2 is hydrogen or methyl;
- R.sub.3 hydroxyl, methyl or hydroxymethyl;
- R.sub.4 and R.sub.5 are hydrogen;
- R.sub.6 is C.sub.1-5 alkyl which may be ranched or contain a double bond;
- and wherein carbons at the 2-3 positions may have double bond.
- 3. A process for treating a patient in need of a tranquilizer which comprises administering to said patient a tranquilizing effective amount of a prostaglandin D represented by formula (I): ##STR26## where (X) is ##STR27## R.sub.1 is hydrogen, a physiologically acceptable salt residue or a physiologically acceptably ester residue;
- R.sub.2 is hydrogen or methyl;
- R.sub.3 is hydroxyl, methyl or hydroxymethyl;
- R.sub.4 and R.sub.5, which may be the same or different, each represents hydrogen or methyl;
- R.sub.6 is C.sub.1-5 alkyl methyl which may be branched or contain a double bond;
- and wherein carbons at the 2-3 positions may have double bond.
- 4. A process for treating a patient in need of a soporific which comprises administering to said patient a soporific effective amount of a prostaglandin D represented by formula (I): ##STR28## where (X) is ##STR29## R.sub.1 is hydrogen, a physiologically acceptable salt residue or a physiologically acceptably ester residue;
- R.sub.2 is hydrogen or methyl;
- R.sub.3 is hydroxyl, methyl or hydroxymethyl;
- R.sub.4 and R.sub.5, which may be the same or different, each represents hydrogen or methyl;
- R.sub.6 is C.sub.1-5 alkyl which may be branched or contain a double bond;
- and wherein carbons at the 2-3 positions may have double bond.
- 5. The process of claim 3 in which R.sub.1 is C.sub.1 -C.sub.4 alkyl group.
- 6. The process of claim 4 in which R.sub.1 is C.sub.1 -C.sub.4 alkyl group.
- 7. The process of claim 3 wherein the R.sub.1 ester residue is selected from the group consisting of a C.sub.1 -C.sub.4 alkyl group, an alkylsilicon group and a tetrahydroxypyran group.
- 8. The process of claim 4 wherein the R.sub.1 ester residue is selected from the group consisting of a C.sub.1 -C.sub.4 alkyl group, an alkylsilicon group and a tetrahydroxypyran group.
- 9. A process of claim 4, wherein both R.sub.4 and R.sub.5 are methyl.
- 10. A process of claim 4, wherein one of R.sub.4 and R.sub.5 is a methyl group and the other is a hydrogen atom.
- 11. A process for treating a patient in need of a tranquilizer which comprises administering to said patient a tranquilizing effective amount of a compound of claim 1.
- 12. A process for treating a patient in need of a tranquilizer which comprises administering to said patient a tranquilizing effective amount of a compound of claim 2.
- 13. A process for treating a patient in need of a soporific which comprises administering to said patient a soporific effective amount of a compound of claim 1.
- 14. A process for treating a patient in need of a soporific which comprises administering to said patient a soporific effective amount of a compound of claim 2.
- 15. A prostaglandin D represented by formula (I): ##STR30## where (X) is ##STR31## R.sub.1 is a physiologically acceptable alkyl ester residue; R.sub.2 is hydrogen or methyl;
- R.sub.3 is hydroxyl, methyl or hydroxymethyl;
- R.sub.4 and R.sub.5, which may be the same or different, each represents hydrogen or methyl;
- R.sub.6 is C.sub.1-5 alkyl which may be branched or contain a double bond;
- and wherein carbons at the 2-3 positions may have a double bond.
- 16. A prostaglandin D represented by formula (I): ##STR32## where (X) is ##STR33## R.sub.1 is hydrogen, a physiologically acceptable salt residue or a physiologically acceptable alkyl ester residue;
- R.sub.2 is hydrogen or methyl;
- R.sub.3 is hydroxyl, methyl or hydroxymethyl; R.sub.4 and R.sub.5, which may be the same or different, each represents hydrogen or methyl;
- R.sub.6 is C.sub.6-9 alkyl which may be branched or contain a double bond;
- and wherein carbons at the 2-3 positions may have a double bond.
- 17. A prostaglandin D of claim 1 or claim 2, in which R.sub.1 is C.sub.1 -C.sub.4 alkyl group.
- 18. A prostaglandin D of claim 1 or claim 2, wherein the R.sub.1 ester residue is selected from the group consisting of a C.sub.1 -C.sub.4 alkyl group, an alkylsilicon group and a tetrahydroxypyran group.
- 19. A prostaglandin D of claim 1, wherein X is A or B.
- 20. A process of claim 3, wherein both R.sub.4 and R.sub.5 are methyl.
- 21. A process of claim 3, wherein R.sub.4 and R.sub.5 is a methyl group and the other is a hydrogen atom.
- 22. A tranquilizer or soporific containing an amount effective as a tranquilizer or soporific of a prostaglandin D of claim 1 as an active ingredient, and a pharmaceutically acceptable carrier.
- 23. A tranquilizer or soporific containing an amount effective as a tranquilizer or soporific of a prostaglandin D of claim 2 as an active ingredient, and a pharmaceutically acceptable carrier.
- 24. A tranquilizer or soporific containing an amount effective as a tranquilizer or soporific of a prostaglandin D of claim 17 as an active ingredient, and a pharmaceutically acceptable carrier.
- 25. A tranquilizer or soporific containing an amount effective as tranquilizer or soporific of a prostaglandin D of claim 18 as an active ingredient, and a pharmaceutically acceptable carrier.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 62-18821 |
Jan 1987 |
JPX |
|
Parent Case Info
This is a Continuation of application Ser. No. 08/043,991 filed Apr. 7, 1993, now abandoned in turn a Continuation of application Ser. No. 07/715,156 filed Jun. 13, 1991, now abandoned, in turn a Continuation of application Ser. No. 07/403,774 filed Sep. 6, 1989, now U.S. Pat. No. 5,073,569, in turn a Continuation-in-Part of application Ser. No. 07/149,272 filed Jan. 28, 1988, abandoned.
Foreign Referenced Citations (1)
| Number |
Date |
Country |
| 2272641 |
Dec 1975 |
FRX |
Non-Patent Literature Citations (3)
| Entry |
| Chemical Abstracts, vol. 86, No. 11 Mar. 14, 1977, p. 69, Abstract No. 65891m, Columbus, Ohio. |
| Chemical Abstracts, vol. 102, No. 19, May 13, 1985, p. 125, Abstract No. 161123g, Columbus, Ohio. |
| Biochemical and Biophysical Research Communications vol. 109, No. 2, 1982, pp. 576-582. |
Continuations (3)
|
Number |
Date |
Country |
| Parent |
43991 |
Apr 1993 |
|
| Parent |
715156 |
Jun 1991 |
|
| Parent |
403774 |
Sep 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
| Parent |
149272 |
Jan 1988 |
|
Patent Grant
5534547
